NCT03780166View on ClinicalTrials.gov

A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

March 31, 2019

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions

Pemphigus Vulgaris

Interventions

DRUG

Parsaclisib

Parsaclisib administered orally once daily at the cohort-specified dose level.

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY